AKT1 and kidney cancer: We also found that some specific molecular pathways play an important role in peptide therapy, such as CIP2A bp inactivating the PI3K/AKT/ NFKB pathway to inhibit the invasion and metastasis of BC [69]; MIAC can activate PI3K/AKT and MAPK to inhibit the proliferation and migration of kidney cancer cells [126], suggesting that we can discover new micropeptides that affect tumor progression from the known molecular pathways affected by micropeptides, which may also be one of the hotspots for future research.